Navigation Links
HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
Date:8/27/2013

without limitation our expectations with respect to the progress of clinical trials and post-approval studies, regulatory status, research and development activities and the commercial launch of the HeartWare® Ventricular Assist System in the U.S.  Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. "Risk Factors" in HeartWare's Annual Report on Form 10-K filed with the Securities and Exchange Commission.  HeartWare may update risk factors from time to time in Part II, Item 1A "Risk Factors" in Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com 
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
2. HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
3. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
4. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
5. HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
8. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
9. HeartWare Schedules First Quarter Conference Call And Webcast
10. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ), ... to MDBX.  The company previously announced that their name ... The company is a leader in the design, manufacture ... The free-standing unit features 60 or more slots that ...
... 2011 This year, the melanoma community saw the first ... This major step forward will give more than 400 party-goers ... Gala.  They will gather at the Trump National Golf Club ... these cutting-edge advances and raise money for future research through ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 3
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting ... Rome, Italy and is hosted by the Salesian Pontifical ... a wide variety of topics such as ADHD, anxiety, ... in athletes. The scientific program will feature the latest ... allows clients to see what is going on in ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... - Company to Webcast Presentation at 9:30 a.m. ET on ... Corporation,(Nasdaq: SMTS ) is scheduled to participate in the ... 22, 2008 at the New York Hilton., Bruce J. ... presentation that will be webcast live on Wednesday,May 21, 2008 ...
... have used cough medicine for children younger than two ... effective for children in this age group, an Australia-first ... and Royal Childrens Hospital study, surveyed 325 parents at ... care centres about their use of over-the-counter medication for ...
... The International Association for Dental Research (IADR) ... winners of the annual IADR/GSK Innovation in Oral ... innovative oral care technologies that may maintain and ... Sharing the $225,000 unrestricted research grant, which is ...
... 2008 Canadian researchers have shown that an electric ... neurologic and neuropsychological symptoms in humans. , Following ... and behavioral aftereffects, such as memory loss and symptoms ... grant from Hydro-Qubec and conducted by clinicians from the ...
... 15, 2008 Physicians and dentists should collaborate to ... or may develop osteoporosis, say researchers in the cover ... the American Dental Association. , The authors of the ... the medical and dental literature to examine osteoporosis effect ...
... with ICG-Guided Therapy On Over 76,000+ ... ... 15 CardioDynamics (Nasdaq:,CDICD), the innovator and leader of Impedance ... today,announced the presentation of a significant independent ICG clinical study,at ...
Cached Medicine News:Health News:Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 2Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 3Health News:Electric shocks can cause neurologic and neuropsychological symptoms 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 3
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Barr periosteal elevators....
Seldin periosteal elevators....
Williger periosteal elevators....
Medicine Products: